This week (May 16 to May 22), the pharmaceutical industry should pay attention to the following events: monkeypox infection cases appear in many countries Cansino Biologics Inc(688185) recombinant novel coronavirus vaccine was included in the “emergency use list” by who Zhejiang Hisun Pharmaceutical Co.Ltd(600267) entrusted to produce covid-19 specific drug vv116 under development.
The details are as follows:
covid-19 epidemic related
Zhejiang Hisun Pharmaceutical Co.Ltd(600267) commissioned to produce covid-19 specific drug vv116
After hours on May 19, Zhejiang Hisun Pharmaceutical Co.Ltd(600267) announced that the company and Wangshi biology had signed the strategic cooperation agreement and the entrusted production framework agreement. The two sides intend to establish strategic cooperation in the fields of product processing, production, international registration and market development of small molecule innovative drug vv116, and Wangshi biology entrusts Zhejiang Hisun Pharmaceutical Co.Ltd(600267) to produce vv116 products.
Vv116 is a small molecule oral drug against covid-19 virus developed by Shanghai Junshi Biosciences Co.Ltd(688180) and Wangshan wangshui in cooperation with Pfizer paxlovid.
Zhejiang Hisun Pharmaceutical Co.Ltd(600267) said that for the above-mentioned entrusted processing of vv116 products, the relevant tablet production line has passed the GMP compliance inspection. In the follow-up, the drug entrusted production can be formally accepted only after the variety is approved for listing and the registration of drug entrusted production is approved.
Join Junshi covid-19 drug camp Zhejiang Hisun Pharmaceutical Co.Ltd(600267) one word limit, which other companies are expected to take a share of the industrial feast?
Cansino Biologics Inc(688185) 5 recombinant novel coronavirus vaccine (adenovirus type 5 vector) was included in the “emergency use list” of who
On the 19th, the Cansino Biologics Inc(688185) announcement said that the recombinant novel coronavirus vaccine (adenovirus type 5 vector) independently developed by enterprises has been included in the “emergencyuselisting” (hereinafter referred to as “Eul”) by who.
The reporter from the WHO official website learned that this is the third domestic vaccine included in the Eul by the who after two covid-19 inactivated vaccines from China biological Beijing Institute of biological products and SVA. O.
How many orders can the who “bring goods” Cansino Biologics Inc(688185) covid-19 vaccine pull?
walk for 15 minutes “sampling circle”
Earlier, Guo Yanhong, the supervisor of the medical administration and medical administration bureau of the National Health Commission, said at the press conference of the joint prevention and control mechanism of the State Council that the establishment of a nucleic acid “sampling circle” in big cities with a 15 minute walk is conducive to Lbx Pharmacy Chain Joint Stock Company(603883) nearby nucleic acid detection, early detection of infection and further improve the sensitivity of epidemic monitoring and early warning.
Investigation on the current situation of nucleic acid detection and sampling kiosks: there are many manufacturers, low technical content and different standards
stephanine
Around May 16, an invention patent was circulated on the Internet. Accordingly, 10 μ mol / L of stephanine inhibited coronavirus replication by 15393 times. The first inventor of the patent is Professor Tong Yigang, Dean of School of life science and technology, Beijing University of chemical technology.
In the secondary market, Yunnan Baiyao Group Co.Ltd(000538) , Bio Valley and other listed companies with the production approval of stephanine, even including Shandong Buchang Pharmaceuticals Co.Ltd(603858) , North China Pharmaceutical Company.Ltd(600812) , Dali Pharmaceutical Co.Ltd(603963) , Zhuzhou Qianjin Pharmaceutical Co.Ltd(600479) and many other stocks without the concept of “stephanine”, have also changed their share prices in the near future due to the “stephanine” in their names or various other connections.
In fact, according to the situation mastered by the reporter of science and Innovation Board daily, the above-mentioned four manufacturers with the production approval of stephanine tablets have stopped the production and sales of stephanine tablets a few years ago.
Focus | basic research shows the miraculous effect of anti covid-19. The four wholesalers have stopped production for many years. Who is promoting the change of stephanine?
other industry events
monkeypox infections occur in many countries
Monkeypox infections occur in many countries. As of May 21, 14 countries such as the UK, the United States, Israel and Switzerland have been infected. According to the World Health Organization, there are about 92 confirmed cases and 28 suspected cases to be confirmed.
Who described the monkeypox epidemic as an “atypical outbreak”. On the one hand, the disease area has changed. Europe and the United States and other “non monkeypox virus endemic countries” are successively reporting cases. On the other hand, the route of virus infection is a mystery. Most cases are more like “local transmission”, and the source of infection is unknown.
92 cases spread to 12 countries! Who: close contact with monkeypox is leading to human to human transmission. More cases may be reported in the next few days
Jiangsu Bioperfectus Technologies Co.Ltd(688399) : monkeypox virus nucleic acid detection kit is only for Disease Control and scientific research
On May 20, Jiangsu Bioperfectus Technologies Co.Ltd(688399) official website showed that the company owned monkeypox virus nucleic acid detection kit (fluorescence PCR method), article number jc70115 The reporter of SciTech Innovation Board daily further learned from Jiangsu Bioperfectus Technologies Co.Ltd(688399) that the company’s product has not obtained the registration certificate at present, and is only used for Disease Control and scientific research.
direct performance meeting
Sino Medical Sciences Technology Inc(688108) : in response to centralized procurement, actively planning for “going to sea”, a new generation of support products have been submitted to the U.S. market application
An Xu biology: revenue growth depends entirely on covid-19 detection of “two / three in one” joint inspection reagent, and then map a new space
Chemclin Diagnostics Co.Ltd(688468) : core products are self-produced with centralized purchase and large-scale raw materials, which has cost advantages
Xiangyumedicalco.Ltd(688626) : R & D investment and the impact of the epidemic on short-term performance, and the long-term trend of the rehabilitation industry is improving
Maider Medical Industry Equipment Co.Ltd(688310) : various factors improve the downstream automation demand. The raised investment project is expected to be completed and put into operation within this year
Hitgen Inc(688222) : del screening and other businesses have shown a recovery trend, and the company’s executives explain the business model in detail
primary market
laikai pharmaceutical completed round D financing of US $61 million
On May 18, laikai pharmaceutical announced that it had recently completed round D financing of US $61 million (about 390 million yuan).
The current round of financing was led by SDIC investment promotion, and the old shareholder yanchuang capital continued to increase its holdings, followed by Wanhui capital and Infiniti capital. As a global cutting-edge biopharmaceutical company in clinical stage, laikai is committed to bringing innovative therapies to patients with cancer and liver disease around the world. At present, there are 14 innovative candidate drugs in the company’s product pipeline, and 6 projects have been approved for clinical research.
Xingrui pharmaceutical completed the round a financing of 150 million yuan
On May 16, Xingrui pharmaceutical, which focuses on the research and development of new mRNA drugs, announced that it had completed a round of financing of 150 million yuan. This round of financing was led by lyfe capital, followed by source capital, Hony capital and Chunhua venture capital. The old shareholders Gaoling venture capital and Sherpa investment continued to increase. The funds raised this time will be used to expand the R & D center, build the pilot workshop and promote the pipeline under research, further improve the extrahepatic delivery technology and broaden the application prospect of mRNA drugs.
Sudan medical announced the completion of tens of millions of yuan of financing
On May 16, Hangzhou Sudan Medical Technology Co., Ltd. completed a financing of tens of millions of yuan, with the joint participation of Shandong health fund and Zhenge fund. It will be mainly used to accelerate the R & D, clinical trials and market-oriented promotion of innovative digital therapy products at the clinical and consumer ends, so as to establish the company’s leading position in the field of digital therapy for neurodegenerative diseases. Founded in 2021, Shudan medical is an innovative digital therapy company based in China and facing the world. It is committed to providing users and patients in China and around the world with brain health innovative digital therapy that breaks through the limitations of traditional medicine.
Weimu medical completed tens of millions of pre-A round of financing
On May 19, Shanghai Weimu Medical Technology Co., Ltd. announced the completion of tens of millions of RMB pre-A round of financing, with IDG capital as the exclusive investment and Dianshi capital as the exclusive financial adviser. The funds raised will be used to promote clinical trials of existing products, expansion of new product pipelines and team expansion.
Established at the end of 2020, Weimu medical is located in Shanghai Lingang Holdings Co.Ltd(600848) life Blue Bay Park. Weimu team has built the first high-end interventional medical device platform based on innovative materials in China, and developed many products such as microspheres, hydrogels and tissue adhesives to solve many unmet clinical needs such as liver cancer and varicose veins of lower limbs.
aikemai completed nearly 100 million yuan of round a financing
On May 20, Suzhou aikemai Medical Technology Co., Ltd. completed a round of financing of nearly 100 million yuan. This round of financing was led by the former master fund, followed by the old shareholders Shanghai biomedical fund and Yuansheng venture capital. Xingyuan Zhitong continues to serve as the exclusive financial advisor. This financing will further establish the moat of Aike pulse in the field of cardiac electrophysiology, accelerate the clinical trial of atrial fibrillation pulsed electric field ablation (PFA) products and the research and development of three-dimensional mapping system and other electrophysiological treatment and mapping products, and help the company become an international leading new generation electrophysiological platform technology company.
Shanghai Yike completed the round B financing of tens of millions of Yuan
On May 22, Shanghai Yike Polymer Technology Co., Ltd. completed a round B financing of tens of millions of yuan, which was exclusively invested by Qiming venture capital. This round of funds will be used for in-depth research and development of medical dialysis membranes and high-end catheters.
In the application field of medical membrane materials, Shanghai Yike focuses on renal dialysis membrane, drug separation membrane, etc. The company has developed a new generation of renal dialysis membrane. At present, it has reached cooperation intentions with many dialyzer customers and made sufficient preparations for the mass production of high-throughput membrane; In terms of medical catheters, Shanghai Yike’s core products include nerve and peripheral micro catheters, disposable endoscopic catheters, etc.
